Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1674-8018
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment ; day:2 ; month:5 ; year:2017 ; pages:1-30
Protein & cell ; (2.5.2017), 1-30
- Keyword
-
Krebs
Onkologie
- Creator
-
Wang, Zhenguang
- Contributor
-
Guo, Yelei
Han, Weidong
SpringerLink (Online service)
- DOI
-
10.1007/s13238-017-0400-z
- URN
-
urn:nbn:de:1111-201705138800
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wang, Zhenguang
- Guo, Yelei
- Han, Weidong
- SpringerLink (Online service)
Other Objects (12)
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Current limitations and perspectives of chimeric antigen receptor-T-cells in acute myeloid leukemia
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
Chimeric Antigen Receptor T-Cell Therapy
Chimeric antigen receptor-modified NK cells target breast carcinomas resistant to soluble antibody treatment
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Targeting and Elimination of T Cell Subpopulations by Chimeric Antigen Receptor-modified T Cells
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Current limitations and perspectives of chimeric antigen receptor-T-cells in acute myeloid leukemia
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
Chimeric Antigen Receptor T-Cell Therapy
Chimeric antigen receptor-modified NK cells target breast carcinomas resistant to soluble antibody treatment
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Targeting and Elimination of T Cell Subpopulations by Chimeric Antigen Receptor-modified T Cells
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Current limitations and perspectives of chimeric antigen receptor-T-cells in acute myeloid leukemia
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
Chimeric Antigen Receptor T-Cell Therapy
Chimeric antigen receptor-modified NK cells target breast carcinomas resistant to soluble antibody treatment
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Targeting and Elimination of T Cell Subpopulations by Chimeric Antigen Receptor-modified T Cells